Study of Targeted Activated Dendritic Cells and CAR-T Therapy for Adults with Advanced Solid Cancers

What this Trial Is About

Researchers are evaluating the safety and early effectiveness of a combination of Targeted Activated Dendritic Cells DCs and CAR-T cell therapy in adults with advanced solid cancers. This early-phase clinical study focuses on how activating dendritic cells can help target tumors more precisely, change the tumor immune environment, and improve the ability of CAR-T cells to attack cancer cells more deeply and persistently. Participants will receive a treatment involving their own genetically modified dendritic cells and T cells, designed to express chimeric antigen receptors CAR. This combined therapy aims to better penetrate tumors and kill cancer cells. The study is open-label and single-arm, meaning all participants receive this combination therapy. The treatment and follow-up will continue for up to two years to monitor effects and safety. During the study, participants will have regular visits for evaluations including laboratory tests, imaging, and monitoring of adverse events for two years after receiving the cell infusion. Researchers will measure safety by tracking adverse events and assess effectiveness by looking at tumor response rates, disease control, progression-free survival, and changes in the immune environment within one month after treatment. Participants must comply with scheduled visits and procedures throughout the study.

Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers